Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
AC220 will be administered as a once daily oral solution given continuously as 28-day
treatment cycles, without food and without any rest periods, as long as there is no evidence
of disease progression or unacceptably severe adverse events (AEs) related to the study drug.